HealthMore in Health→
FDA Reopens a Rare Cancer Drug Review After a Surprise Rejection
Key Takeaways
- The FDA is reconsidering Ebvallo after previously rejecting the treatment.
- STAT’s candidate metadata describes the earlier decision as a surprise rejection.
- The companies developing Ebvallo reached an agreement with the FDA to address the main reason for the rejection.
DE
DT Editorial Team··via statnews.com